The global Influenza Antiviral Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Influenza Antiviral Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Influenza Antiviral Drugs.

Report Scope

The Influenza Antiviral Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Influenza Antiviral Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Influenza Antiviral Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Influenza Antiviral Drugs Market Report

Report Metric	Details
Report Name	Influenza Antiviral Drugs Market
CAGR	5%
Segment by Type	Oseltamivir Zanamivir Peramivir Adamantanes Others
Segment by Application	Hospitals Clinics Ambulatory Surgical Centers Pharmacies Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	GSK, Boehringer Ingelheim, Merck, Novartis, Beximco Pharmaceuticals, Pfizer, Roche, Johnson & Johnson, Sanofi, Cipla Limited, Natco Pharma, Seqirus, Adamas Pharmaceuticals, Inc., Teva Pharmaceuticals, Daiichi Sankyo Company
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Influenza Antiviral Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Influenza Antiviral Drugs Market report?

Ans: The main players in the Influenza Antiviral Drugs Market are GSK, Boehringer Ingelheim, Merck, Novartis, Beximco Pharmaceuticals, Pfizer, Roche, Johnson & Johnson, Sanofi, Cipla Limited, Natco Pharma, Seqirus, Adamas Pharmaceuticals, Inc., Teva Pharmaceuticals, Daiichi Sankyo Company

What are the Application segmentation covered in the Influenza Antiviral Drugs Market report?

Ans: The Applications covered in the Influenza Antiviral Drugs Market report are Hospitals, Clinics, Ambulatory Surgical Centers, Pharmacies, Others

What are the Type segmentation covered in the Influenza Antiviral Drugs Market report?

Ans: The Types covered in the Influenza Antiviral Drugs Market report are Oseltamivir, Zanamivir, Peramivir, Adamantanes, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Influenza Antiviral Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Oseltamivir

1.2.3 Zanamivir

1.2.4 Peramivir

1.2.5 Adamantanes

1.2.6 Others

1.3 Market by Application

1.3.1 Global Influenza Antiviral Drugs Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Ambulatory Surgical Centers

1.3.5 Pharmacies

1.3.6 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Influenza Antiviral Drugs Market Perspective (2019-2030)

2.2 Influenza Antiviral Drugs Growth Trends by Region

2.2.1 Global Influenza Antiviral Drugs Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Influenza Antiviral Drugs Historic Market Size by Region (2019-2024)

2.2.3 Influenza Antiviral Drugs Forecasted Market Size by Region (2025-2030)

2.3 Influenza Antiviral Drugs Market Dynamics

2.3.1 Influenza Antiviral Drugs Industry Trends

2.3.2 Influenza Antiviral Drugs Market Drivers

2.3.3 Influenza Antiviral Drugs Market Challenges

2.3.4 Influenza Antiviral Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Influenza Antiviral Drugs Players by Revenue

3.1.1 Global Top Influenza Antiviral Drugs Players by Revenue (2019-2024)

3.1.2 Global Influenza Antiviral Drugs Revenue Market Share by Players (2019-2024)

3.2 Global Influenza Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Influenza Antiviral Drugs Revenue

3.4 Global Influenza Antiviral Drugs Market Concentration Ratio

3.4.1 Global Influenza Antiviral Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Influenza Antiviral Drugs Revenue in 2023

3.5 Influenza Antiviral Drugs Key Players Head office and Area Served

3.6 Key Players Influenza Antiviral Drugs Product Solution and Service

3.7 Date of Enter into Influenza Antiviral Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Influenza Antiviral Drugs Breakdown Data by Type

4.1 Global Influenza Antiviral Drugs Historic Market Size by Type (2019-2024)

4.2 Global Influenza Antiviral Drugs Forecasted Market Size by Type (2025-2030)

5 Influenza Antiviral Drugs Breakdown Data by Application

5.1 Global Influenza Antiviral Drugs Historic Market Size by Application (2019-2024)

5.2 Global Influenza Antiviral Drugs Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Influenza Antiviral Drugs Market Size (2019-2030)

6.2 North America Influenza Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Influenza Antiviral Drugs Market Size by Country (2019-2024)

6.4 North America Influenza Antiviral Drugs Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Influenza Antiviral Drugs Market Size (2019-2030)

7.2 Europe Influenza Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Influenza Antiviral Drugs Market Size by Country (2019-2024)

7.4 Europe Influenza Antiviral Drugs Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Influenza Antiviral Drugs Market Size (2019-2030)

8.2 Asia-Pacific Influenza Antiviral Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2019-2024)

8.4 Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Influenza Antiviral Drugs Market Size (2019-2030)

9.2 Latin America Influenza Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Influenza Antiviral Drugs Market Size by Country (2019-2024)

9.4 Latin America Influenza Antiviral Drugs Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Influenza Antiviral Drugs Market Size (2019-2030)

10.2 Middle East & Africa Influenza Antiviral Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2019-2024)

10.4 Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 GSK

11.1.1 GSK Company Detail

11.1.2 GSK Business Overview

11.1.3 GSK Influenza Antiviral Drugs Introduction

11.1.4 GSK Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.1.5 GSK Recent Development

11.2 Boehringer Ingelheim

11.2.1 Boehringer Ingelheim Company Detail

11.2.2 Boehringer Ingelheim Business Overview

11.2.3 Boehringer Ingelheim Influenza Antiviral Drugs Introduction

11.2.4 Boehringer Ingelheim Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.2.5 Boehringer Ingelheim Recent Development

11.3 Merck

11.3.1 Merck Company Detail

11.3.2 Merck Business Overview

11.3.3 Merck Influenza Antiviral Drugs Introduction

11.3.4 Merck Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.3.5 Merck Recent Development

11.4 Novartis

11.4.1 Novartis Company Detail

11.4.2 Novartis Business Overview

11.4.3 Novartis Influenza Antiviral Drugs Introduction

11.4.4 Novartis Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.4.5 Novartis Recent Development

11.5 Beximco Pharmaceuticals

11.5.1 Beximco Pharmaceuticals Company Detail

11.5.2 Beximco Pharmaceuticals Business Overview

11.5.3 Beximco Pharmaceuticals Influenza Antiviral Drugs Introduction

11.5.4 Beximco Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.5.5 Beximco Pharmaceuticals Recent Development

11.6 Pfizer

11.6.1 Pfizer Company Detail

11.6.2 Pfizer Business Overview

11.6.3 Pfizer Influenza Antiviral Drugs Introduction

11.6.4 Pfizer Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.6.5 Pfizer Recent Development

11.7 Roche

11.7.1 Roche Company Detail

11.7.2 Roche Business Overview

11.7.3 Roche Influenza Antiviral Drugs Introduction

11.7.4 Roche Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.7.5 Roche Recent Development

11.8 Johnson & Johnson

11.8.1 Johnson & Johnson Company Detail

11.8.2 Johnson & Johnson Business Overview

11.8.3 Johnson & Johnson Influenza Antiviral Drugs Introduction

11.8.4 Johnson & Johnson Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.8.5 Johnson & Johnson Recent Development

11.9 Sanofi

11.9.1 Sanofi Company Detail

11.9.2 Sanofi Business Overview

11.9.3 Sanofi Influenza Antiviral Drugs Introduction

11.9.4 Sanofi Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.9.5 Sanofi Recent Development

11.10 Cipla Limited

11.10.1 Cipla Limited Company Detail

11.10.2 Cipla Limited Business Overview

11.10.3 Cipla Limited Influenza Antiviral Drugs Introduction

11.10.4 Cipla Limited Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.10.5 Cipla Limited Recent Development

11.11 Natco Pharma

11.11.1 Natco Pharma Company Detail

11.11.2 Natco Pharma Business Overview

11.11.3 Natco Pharma Influenza Antiviral Drugs Introduction

11.11.4 Natco Pharma Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.11.5 Natco Pharma Recent Development

11.12 Seqirus

11.12.1 Seqirus Company Detail

11.12.2 Seqirus Business Overview

11.12.3 Seqirus Influenza Antiviral Drugs Introduction

11.12.4 Seqirus Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.12.5 Seqirus Recent Development

11.13 Adamas Pharmaceuticals, Inc.

11.13.1 Adamas Pharmaceuticals, Inc. Company Detail

11.13.2 Adamas Pharmaceuticals, Inc. Business Overview

11.13.3 Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Introduction

11.13.4 Adamas Pharmaceuticals, Inc. Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.13.5 Adamas Pharmaceuticals, Inc. Recent Development

11.14 Teva Pharmaceuticals

11.14.1 Teva Pharmaceuticals Company Detail

11.14.2 Teva Pharmaceuticals Business Overview

11.14.3 Teva Pharmaceuticals Influenza Antiviral Drugs Introduction

11.14.4 Teva Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.14.5 Teva Pharmaceuticals Recent Development

11.15 Daiichi Sankyo Company

11.15.1 Daiichi Sankyo Company Company Detail

11.15.2 Daiichi Sankyo Company Business Overview

11.15.3 Daiichi Sankyo Company Influenza Antiviral Drugs Introduction

11.15.4 Daiichi Sankyo Company Revenue in Influenza Antiviral Drugs Business (2019-2024)

11.15.5 Daiichi Sankyo Company Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Beximco Pharmaceuticals

Adamas Pharmaceuticals Inc

Teva Pharmaceuticals

Daiichi Sankyo Company

List of Tables

Table 1. Global Influenza Antiviral Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Oseltamivir

Table 3. Key Players of Zanamivir

Table 4. Key Players of Peramivir

Table 5. Key Players of Adamantanes

Table 6. Key Players of Others

Table 7. Global Influenza Antiviral Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Influenza Antiviral Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Influenza Antiviral Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Influenza Antiviral Drugs Market Share by Region (2019-2024)

Table 11. Global Influenza Antiviral Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Influenza Antiviral Drugs Market Share by Region (2025-2030)

Table 13. Influenza Antiviral Drugs Market Trends

Table 14. Influenza Antiviral Drugs Market Drivers

Table 15. Influenza Antiviral Drugs Market Challenges

Table 16. Influenza Antiviral Drugs Market Restraints

Table 17. Global Influenza Antiviral Drugs Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Influenza Antiviral Drugs Market Share by Players (2019-2024)

Table 19. Global Top Influenza Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2023)

Table 20. Ranking of Global Top Influenza Antiviral Drugs Companies by Revenue (US$ Million) in 2023

Table 21. Global 5 Largest Players Market Share by Influenza Antiviral Drugs Revenue (CR5 and HHI) & (2019-2024)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Influenza Antiviral Drugs Product Solution and Service

Table 24. Date of Enter into Influenza Antiviral Drugs Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Influenza Antiviral Drugs Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Influenza Antiviral Drugs Revenue Market Share by Type (2019-2024)

Table 28. Global Influenza Antiviral Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Influenza Antiviral Drugs Revenue Market Share by Type (2025-2030)

Table 30. Global Influenza Antiviral Drugs Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Influenza Antiviral Drugs Revenue Market Share by Application (2019-2024)

Table 32. Global Influenza Antiviral Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Influenza Antiviral Drugs Revenue Market Share by Application (2025-2030)

Table 34. North America Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. North America Influenza Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 36. North America Influenza Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 37. Europe Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Europe Influenza Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 39. Europe Influenza Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 40. Asia-Pacific Influenza Antiviral Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 41. Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2019-2024) & (US$ Million)

Table 42. Asia-Pacific Influenza Antiviral Drugs Market Size by Region (2025-2030) & (US$ Million)

Table 43. Latin America Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Latin America Influenza Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 45. Latin America Influenza Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 46. Middle East & Africa Influenza Antiviral Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 47. Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2019-2024) & (US$ Million)

Table 48. Middle East & Africa Influenza Antiviral Drugs Market Size by Country (2025-2030) & (US$ Million)

Table 49. GSK Company Detail

Table 50. GSK Business Overview

Table 51. GSK Influenza Antiviral Drugs Product

Table 52. GSK Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 53. GSK Recent Development

Table 54. Boehringer Ingelheim Company Detail

Table 55. Boehringer Ingelheim Business Overview

Table 56. Boehringer Ingelheim Influenza Antiviral Drugs Product

Table 57. Boehringer Ingelheim Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 58. Boehringer Ingelheim Recent Development

Table 59. Merck Company Detail

Table 60. Merck Business Overview

Table 61. Merck Influenza Antiviral Drugs Product

Table 62. Merck Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 63. Merck Recent Development

Table 64. Novartis Company Detail

Table 65. Novartis Business Overview

Table 66. Novartis Influenza Antiviral Drugs Product

Table 67. Novartis Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 68. Novartis Recent Development

Table 69. Beximco Pharmaceuticals Company Detail

Table 70. Beximco Pharmaceuticals Business Overview

Table 71. Beximco Pharmaceuticals Influenza Antiviral Drugs Product

Table 72. Beximco Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 73. Beximco Pharmaceuticals Recent Development

Table 74. Pfizer Company Detail

Table 75. Pfizer Business Overview

Table 76. Pfizer Influenza Antiviral Drugs Product

Table 77. Pfizer Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 78. Pfizer Recent Development

Table 79. Roche Company Detail

Table 80. Roche Business Overview

Table 81. Roche Influenza Antiviral Drugs Product

Table 82. Roche Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 83. Roche Recent Development

Table 84. Johnson & Johnson Company Detail

Table 85. Johnson & Johnson Business Overview

Table 86. Johnson & Johnson Influenza Antiviral Drugs Product

Table 87. Johnson & Johnson Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 88. Johnson & Johnson Recent Development

Table 89. Sanofi Company Detail

Table 90. Sanofi Business Overview

Table 91. Sanofi Influenza Antiviral Drugs Product

Table 92. Sanofi Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 93. Sanofi Recent Development

Table 94. Cipla Limited Company Detail

Table 95. Cipla Limited Business Overview

Table 96. Cipla Limited Influenza Antiviral Drugs Product

Table 97. Cipla Limited Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 98. Cipla Limited Recent Development

Table 99. Natco Pharma Company Detail

Table 100. Natco Pharma Business Overview

Table 101. Natco Pharma Influenza Antiviral Drugs Product

Table 102. Natco Pharma Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 103. Natco Pharma Recent Development

Table 104. Seqirus Company Detail

Table 105. Seqirus Business Overview

Table 106. Seqirus Influenza Antiviral Drugs Product

Table 107. Seqirus Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 108. Seqirus Recent Development

Table 109. Adamas Pharmaceuticals, Inc. Company Detail

Table 110. Adamas Pharmaceuticals, Inc. Business Overview

Table 111. Adamas Pharmaceuticals, Inc. Influenza Antiviral Drugs Product

Table 112. Adamas Pharmaceuticals, Inc. Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 113. Adamas Pharmaceuticals, Inc. Recent Development

Table 114. Teva Pharmaceuticals Company Detail

Table 115. Teva Pharmaceuticals Business Overview

Table 116. Teva Pharmaceuticals Influenza Antiviral Drugs Product

Table 117. Teva Pharmaceuticals Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 118. Teva Pharmaceuticals Recent Development

Table 119. Daiichi Sankyo Company Company Detail

Table 120. Daiichi Sankyo Company Business Overview

Table 121. Daiichi Sankyo Company Influenza Antiviral Drugs Product

Table 122. Daiichi Sankyo Company Revenue in Influenza Antiviral Drugs Business (2019-2024) & (US$ Million)

Table 123. Daiichi Sankyo Company Recent Development

Table 124. Research Programs/Design for This Report

Table 125. Key Data Information from Secondary Sources

Table 126. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Influenza Antiviral Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Influenza Antiviral Drugs Market Share by Type: 2023 VS 2030

Figure 3. Oseltamivir Features

Figure 4. Zanamivir Features

Figure 5. Peramivir Features

Figure 6. Adamantanes Features

Figure 7. Others Features

Figure 8. Global Influenza Antiviral Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Influenza Antiviral Drugs Market Share by Application: 2023 VS 2030

Figure 10. Hospitals Case Studies

Figure 11. Clinics Case Studies

Figure 12. Ambulatory Surgical Centers Case Studies

Figure 13. Pharmacies Case Studies

Figure 14. Others Case Studies

Figure 15. Influenza Antiviral Drugs Report Years Considered

Figure 16. Global Influenza Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global Influenza Antiviral Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Influenza Antiviral Drugs Market Share by Region: 2023 VS 2030

Figure 19. Global Influenza Antiviral Drugs Market Share by Players in 2023

Figure 20. Global Top Influenza Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Antiviral Drugs as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by Influenza Antiviral Drugs Revenue in 2023

Figure 22. North America Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America Influenza Antiviral Drugs Market Share by Country (2019-2030)

Figure 24. United States Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Canada Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Europe Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Influenza Antiviral Drugs Market Share by Country (2019-2030)

Figure 28. Germany Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. France Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. U.K. Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Italy Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Russia Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Nordic Countries Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Asia-Pacific Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Influenza Antiviral Drugs Market Share by Region (2019-2030)

Figure 36. China Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Japan Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. South Korea Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Southeast Asia Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. India Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Australia Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Latin America Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Influenza Antiviral Drugs Market Share by Country (2019-2030)

Figure 44. Mexico Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Brazil Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Middle East & Africa Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Influenza Antiviral Drugs Market Share by Country (2019-2030)

Figure 48. Turkey Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. Saudi Arabia Influenza Antiviral Drugs Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. GSK Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 51. Boehringer Ingelheim Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 52. Merck Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 53. Novartis Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 54. Beximco Pharmaceuticals Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 55. Pfizer Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 56. Roche Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 57. Johnson & Johnson Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 58. Sanofi Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 59. Cipla Limited Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 60. Natco Pharma Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 61. Seqirus Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 62. Adamas Pharmaceuticals, Inc. Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 63. Teva Pharmaceuticals Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 64. Daiichi Sankyo Company Revenue Growth Rate in Influenza Antiviral Drugs Business (2019-2024)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Antiviral Drugs Market

Influenza Diagnostics Market

Antiviral Therapy Market

HIV Therapeutics Market

Protease Inhibitors Market

Hepatitis B Therapeutics Market

Anti Viral Coatings Market

Sterile and Antiviral Packaging Market

Specific Antiviral Drugs for COVID 19 Market

Novel Antiviral Drugs Market

Direct acting Antiviral Drugs Market

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions